Clinical Trial Update: Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of exploratory formulations of insulin degludec and IDegAsp 50 in healthy Ja…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• IDegAsp 50 (insulin degludec/insulin aspart) (insulin degludec/insulin aspart)
• insulin degludec (Tresiba) (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED